{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"42.440","rs_stock_flag":false,"fiscal_year_end":"31 Dec 2025","hist_closedate":"25 Sep 2025","replication_method":null,"amt_os":"113,926,864","primaryexch":"HKEX","ric":"2561.HK","product_subtype":null,"db_updatetime":"26 Sep 2025 18:38","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":null,"inline_upper_strike_price":"","sedol":"BPCXBJ7","am":"3.75","iv":"","ew_strike":"","as":"41.880","geographic_focus":null,"incorpin":"Cayman Islands","etp_baseCur":null,"ew_amt_os":"","bd":"41.680","registrar":"Computershare Hong Kong Investor Services Ltd.","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"100","update_time":"2025-09-26 10:38:37.0","lo52":"39.250","shares_issued_date":"31 Aug 2025","premium":"","strike_price_ccy":null,"yield":"","vo_u":"K","base_currency":null,"coupon":"","expiry_date":"","chairman":"Fu Shan","underlying_ric":"2561.HK","hi52":"69.150","issuer_name":"VISEN Pharmaceuticals - B","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"26 Sep 2025 15:48","aum_date":"","lo":"41.100","mkt_cap":"4.74","f_aum_hkd":null,"ew_sub_per_to":"","ls":"41.680","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"Healthcare - Pharmaceuticals & Biotechnology","ew_desc":null,"inception_date":"","nc":"+0.020","aum":"","issued_shares_class_B":null,"vo":"89.38","secondary_listing_flag":false,"listing_date":"21 Mar 2025","issued_shares_class_A":null,"as_at_label":"as at","ew_amt_os_dat":"","nm":"VISEN Pharmaceuticals - B","nm_s":"VISEN PHARMA-B","sym":"2561","inline_lower_strike_price":"","listing_category":"Primary Listing","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.020","strike_price":"","summary":"Visen Pharmaceuticals is a holding company mainly engaged in developing and commercializing disruptive endocrine therapies. The Company's main products under development include lonapegsomatropin, navepegritide, and palopegteriparatide. The lonapegsomatropin is used to treat growth hormone deficiency in children aged 3 to 17 years old. The navepegritide is a disease repair therapy used to treat children with cartilage dysplasia aged 2 to 10 years old. The palopegteriparatide is a treatment method used to treat adult hypoparathyroidism. The Company is in the late stage of research and development, and its products are close to commercialization.","op":"41.660","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"Biotechnology","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"Room 1919, 19/F<br/>Lee Garden One<br/>33 Hysan Avenue<br/>Causeway Bay, Hong Kong","pc":"+0.05","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":null,"hdr":false,"launch_date":"","hc":"41.660","isin":"KYG93Y5D1039","moneyness":""}},"qid":"1758890490911"}
